Karyopharm Therapeutics Inc
KPTI
查看详细走势图
6.260USD
+0.170+2.79%
收盘 02/06, 16:00（美东）报价延迟15分钟
54.47M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.79%
5天
-3.99%
1月
-20.46%
6月
+57.68%
今年开始到现在
-14.95%
1年
-33.86%
查看详细走势图
TradingKey Karyopharm Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Karyopharm Therapeutics Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名95/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价15.40。中期看，股价处于上升通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Karyopharm Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Karyopharm Therapeutics Inc亮点
亮点风险
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
分析师目标
根据
7
位分析师
买入
评级
15.400
目标均价
+144.44%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Karyopharm Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Karyopharm Therapeutics Inc简介
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
公司代码KPTI
公司Karyopharm Therapeutics Inc
CEOPaulson (Richard A)
网址https://karyopharm.com/
相关品种
